BioCentury
ARTICLE | Company News

I-Mab, ABL partner in antibody deals

July 27, 2018 7:30 PM UTC

I-Mab Biopharma (Shanghai, China) granted ABL Bio Inc. (Seongnam, South Korea) rights to bispecific antibodies against an undisclosed target for $2.5 million up front and up to $97.5 million in milestones, plus royalties. ABL will receive worldwide rights to the program outside of China, including Hong Kong and Macau, and Taiwan.

The companies also partnered to develop three additional bispecific antibody programs against undisclosed targets, for which ABL and I-Mab will share development costs and rights worldwide...